Slew of injection-free COVID vaccines are in the pipeline

As vaccine makers pursue the next generation of COVID-19 vaccines, some are working to develop products that wouldn’t require a shot.

Why it matters: Delivering a vaccine through a pill or a nasal spray could make them much easier to administer, especially in places where distribution is challenging — or even for people who just don’t like needles.

San Francisco-based biotech Vaxart is working on a COVID vaccine that would be delivered in an oral tablet.

India’s Bharat Biotech advanced its nasal COVID-19 vaccine candidate into a phase 2 clinical trial earlier this fall.

…

Related on the SLP

No related posts.

Abortion rights opponents outraged after FDA says its “safety review” of the already-found-safe mifepristone abortion pill will continue into 2027

GAHA: The corporate-created “healthier America” movement challenging what it claims is MAHA misinformation about modern farming, chemicals, and food

9 wellness myths busted

Vaxart began enrolling about 100 people in a Phase 2a clinical trial last month and expects to have a readout of that efficacy trial in the first quarter of 2022.

Vaxart’s vaccine showed promise in animal trials, the results of which were published in early October.

What’s next: Even if everything continues to go well, the earliest the company would be able to apply for an emergency use authorization from the FDA is still at least a year to 18 months away — but the world will still need COVID vaccines in a year to 18 months.

This is an excerpt. Read the original post here.